BACKGROUND Lisfranc injuries have not received much attention by orthopedic doctors in the past,and there is little related research on the diagnosis and treatment of these injuries.In recent years with the rise in fo...BACKGROUND Lisfranc injuries have not received much attention by orthopedic doctors in the past,and there is little related research on the diagnosis and treatment of these injuries.In recent years with the rise in foot and ankle surgery,doctors are now paying more attention to this type of injury.However,there is still a high rate of missed diagnosis due to insufficient attention causing treatment delays or inadequate treatments,which eventually result in greater sequelae;including long-term pain,arthritis,foot deformity etc.In particular,for cases with a mild Lisfranc joint complex injury,the incidence of sequelae is higher.AIM To select an active surgical treatment for an atypical Lisfranc joint complex injury and to evaluate the clinical efficacy of the surgical treatment.METHODS The clinical data of 18 patients,including 10 males and 8 females aged 20-64 years with Lisfranc injuries treated in our department from January 2017 to September 2019 were retrospectively analyzed.All patients were treated with an open reduction and internal fixation method using locking titanium mini-plates and hollow screws or Kirschner wires.X-ray images were taken and follow-up was performed monthly after the operation;the internal fixation was then removed 4-5 mo after the operation;and the American Orthopedic Foot and Ankle Society(AOFAS)score was used for evaluation on the last follow-up.RESULTS All patients were followed up for 6-12 mo.A good/excellent AOFAS score was observed in 88.9%of patients.CONCLUSION For atypical Lisfranc joint complex injuries,active open reduction and internal fixation can be performed to enable patients to obtain a good prognosis and satisfactory functional recovery.展开更多
The objective of our study was to explore the possibility of the antifungal efficacy of various micafungin dosage regimens against <i>Candida spp</i> in HIV positive patients with EC. According to pharmaco...The objective of our study was to explore the possibility of the antifungal efficacy of various micafungin dosage regimens against <i>Candida spp</i> in HIV positive patients with EC. According to pharmacokinetic/pharmacodynamics parameters of micafungin in HIV positive patients and MICs distribution of micafungin against <i>Candida spp</i>. in published studies, the dosage regimens of micafungin were 50, 100 and 150 mg QD iv. Monte Carlo Simulation analysed the probability of target attainment and cumulative fraction of response. The results showed that micafungin has good antifungal effect in treating HIV positive patients with EC when pathomycetes are <i>Candida albicans</i>, <i>Candida glabrata</i> or <i>Candida tropicalis</i>, in dosage at 100 mg QD and 150 mg QD.展开更多
<b><span style="font-family:Verdana;">Objective: </span></b><span style="font-family:""><span style="font-family:Verdana;">To select the ingredien...<b><span style="font-family:Verdana;">Objective: </span></b><span style="font-family:""><span style="font-family:Verdana;">To select the ingredients and targets of Yiqing capsule in treating COVID-19 based on network pharmacology, then to explore the potential mechanism of Yiqing capsule in treating COVID-19. </span><b><span style="font-family:Verdana;">Methods:</span></b> </span><span style="font-family:Verdana;">We </span><span style="font-family:Verdana;">screened the ingredients and targets of Yiqing capsule on Traditional Chinese Medicine Systems Pharmacology Database and Analysis Platform (TCMSP), and target genes for COVID-19 in GeneCards database</span><span style="font-family:Verdana;">,</span><span style="font-family:Verdana;"> constructed drug-ingredient-target</span><span style="font-family:Verdana;"> network through software Cytoscape 3.7.2</span><span style="font-family:Verdana;">,</span><span style="font-family:""> </span><span style="font-family:Verdana;">and </span><span style="font-family:Verdana;">constructed protein protein interaction network (PPI) network through STRING database. Gene Ontology (GO) enrichment analysis and Kyoto Encyclopedia of Genes and Genomes (KEGG) analysis of key gene targets of Yiqing capsule </span><span style="font-family:Verdana;">are used to</span><span style="font-family:""><span style="font-family:Verdana;"> treat COVID-19 through software R5.3.2. </span><b><span style="font-family:Verdana;">Results</span></b></span><b><span style="font-family:Verdana;">: </span></b><span style="font-family:""><span style="font-family:Verdana;">We got 42 ingredients, 42 potential therapeutic targets, 1643 GO items and 970 pathways in our study. The main pathway including IL-17 signaling pathway, Chagas disease (American trypanosomiasis), Influenza A, and TNF signaling pathway. </span><b><span style="font-family:Verdana;">Conclusion</span></b></span><b><span style="font-family:Verdana;">: </span></b><span style="font-family:Verdana;">Yiqing capsule plays a role in treating COVID-19 through multiple ingredients, multiple targets and multiple pathways.展开更多
基金Science Foundation of Shenyang Medical College,No.20187076.
文摘BACKGROUND Lisfranc injuries have not received much attention by orthopedic doctors in the past,and there is little related research on the diagnosis and treatment of these injuries.In recent years with the rise in foot and ankle surgery,doctors are now paying more attention to this type of injury.However,there is still a high rate of missed diagnosis due to insufficient attention causing treatment delays or inadequate treatments,which eventually result in greater sequelae;including long-term pain,arthritis,foot deformity etc.In particular,for cases with a mild Lisfranc joint complex injury,the incidence of sequelae is higher.AIM To select an active surgical treatment for an atypical Lisfranc joint complex injury and to evaluate the clinical efficacy of the surgical treatment.METHODS The clinical data of 18 patients,including 10 males and 8 females aged 20-64 years with Lisfranc injuries treated in our department from January 2017 to September 2019 were retrospectively analyzed.All patients were treated with an open reduction and internal fixation method using locking titanium mini-plates and hollow screws or Kirschner wires.X-ray images were taken and follow-up was performed monthly after the operation;the internal fixation was then removed 4-5 mo after the operation;and the American Orthopedic Foot and Ankle Society(AOFAS)score was used for evaluation on the last follow-up.RESULTS All patients were followed up for 6-12 mo.A good/excellent AOFAS score was observed in 88.9%of patients.CONCLUSION For atypical Lisfranc joint complex injuries,active open reduction and internal fixation can be performed to enable patients to obtain a good prognosis and satisfactory functional recovery.
文摘The objective of our study was to explore the possibility of the antifungal efficacy of various micafungin dosage regimens against <i>Candida spp</i> in HIV positive patients with EC. According to pharmacokinetic/pharmacodynamics parameters of micafungin in HIV positive patients and MICs distribution of micafungin against <i>Candida spp</i>. in published studies, the dosage regimens of micafungin were 50, 100 and 150 mg QD iv. Monte Carlo Simulation analysed the probability of target attainment and cumulative fraction of response. The results showed that micafungin has good antifungal effect in treating HIV positive patients with EC when pathomycetes are <i>Candida albicans</i>, <i>Candida glabrata</i> or <i>Candida tropicalis</i>, in dosage at 100 mg QD and 150 mg QD.
文摘<b><span style="font-family:Verdana;">Objective: </span></b><span style="font-family:""><span style="font-family:Verdana;">To select the ingredients and targets of Yiqing capsule in treating COVID-19 based on network pharmacology, then to explore the potential mechanism of Yiqing capsule in treating COVID-19. </span><b><span style="font-family:Verdana;">Methods:</span></b> </span><span style="font-family:Verdana;">We </span><span style="font-family:Verdana;">screened the ingredients and targets of Yiqing capsule on Traditional Chinese Medicine Systems Pharmacology Database and Analysis Platform (TCMSP), and target genes for COVID-19 in GeneCards database</span><span style="font-family:Verdana;">,</span><span style="font-family:Verdana;"> constructed drug-ingredient-target</span><span style="font-family:Verdana;"> network through software Cytoscape 3.7.2</span><span style="font-family:Verdana;">,</span><span style="font-family:""> </span><span style="font-family:Verdana;">and </span><span style="font-family:Verdana;">constructed protein protein interaction network (PPI) network through STRING database. Gene Ontology (GO) enrichment analysis and Kyoto Encyclopedia of Genes and Genomes (KEGG) analysis of key gene targets of Yiqing capsule </span><span style="font-family:Verdana;">are used to</span><span style="font-family:""><span style="font-family:Verdana;"> treat COVID-19 through software R5.3.2. </span><b><span style="font-family:Verdana;">Results</span></b></span><b><span style="font-family:Verdana;">: </span></b><span style="font-family:""><span style="font-family:Verdana;">We got 42 ingredients, 42 potential therapeutic targets, 1643 GO items and 970 pathways in our study. The main pathway including IL-17 signaling pathway, Chagas disease (American trypanosomiasis), Influenza A, and TNF signaling pathway. </span><b><span style="font-family:Verdana;">Conclusion</span></b></span><b><span style="font-family:Verdana;">: </span></b><span style="font-family:Verdana;">Yiqing capsule plays a role in treating COVID-19 through multiple ingredients, multiple targets and multiple pathways.
